Clinical Trials Directory

Trials / Unknown

UnknownNCT04106596

HLA Analysis in Autoimmune Encephalitis and Related Disorders

Immunogenetic Characteristics in Autoimmune Encephalitis and Related Disorders: HLA Analysis

Status
Unknown
Phase
Study type
Observational
Enrollment
160 (estimated)
Sponsor
Hospices Civils de Lyon · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Autoimmune encephalitis (AE) are characterized by subacute onset of memory deficits, altered mental status or psychiatric symptoms, frequently associated with seizures, inflammatory cerebrospinal fluid and in cases with prominent limbic involvement, typical magnetic resonance imaging. Several autoantibodies (Ab) may be detected in AE, although its detection is not mandatory to establish a diagnosis. These Ab mainly recognize different synaptic and cell-surface proteins in the central nervous system, and are thought to be pathogenic as they alter the normal location or function of its antigens. The primary trigger of the immune response is unknown for most of AE. In addition to acquired susceptibility, genetic predisposition may also be important in the pathogenesis of AE. Human leukocyte antigen (HLA) is the genetic factor most frequently associated with autoimmune diseases, due to its genetic complexity and key role in the adaptive immune response. The aim of the study is to describe HLA profile in three groups of autoimmune encephalitis and related disorders: anti-LGI1, anti-CASPR2 and anti-GAD neurological diseases.

Conditions

Timeline

Start date
2019-10-01
Primary completion
2020-02-01
Completion
2020-10-01
First posted
2019-09-27
Last updated
2019-09-27

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04106596. Inclusion in this directory is not an endorsement.